论文部分内容阅读
目的观察ABCG8 T400K基因多态性与阿托伐他汀降脂疗效的关系。方法选取186例高脂血症病人(男、女各93例),口服阿托伐他汀(20mg,qd)治疗4wk,采用聚合酶链反应-限制性片断长度多态性(PCR-RFLP)的方法检测ABCG8 T400K基因多态性,测定治疗前后血清三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白(LDL-C)及高密度脂蛋白(HDL-C)水平。结果ABCG8 T400K的变异频率为0.128;阿托伐他汀治疗后ABCG8 400K等位基因(TK+KK型)携带者HDL-C水平有升高的趋势,且经调整年龄、性别及治疗前血清TG、TC、LDL-C、HDL-C水平后,其HDL-C的变化率显著高于ABCG8 400T纯合子(TT型)携带者((2.8±s11.7)%vs(-0.9±8.4)%,P=0.014));而ABCG8 T400K基因多态性对阿托伐他汀治疗4wk后TG、TC、LDL-C的变化率无明显影响。结论ABCG8 T400K基因多态性可能影响阿托伐他汀改变高密度脂蛋白的疗效。
Objective To observe the relationship between ABCG8 T400K gene polymorphism and lipid lowering efficacy of atorvastatin. Methods A total of 186 patients with hyperlipidemia (93 males and 93 females) were treated with atorvastatin (20 mg, qd) for 4 weeks. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) Methods The gene polymorphism of ABCG8 T400K was detected and the levels of triglyceride (TG), total cholesterol (TC), low density lipoprotein (LDL-C) and high density lipoprotein (HDL-C) were measured before and after treatment. Results The mutation frequency of ABCG8 T400K was 0.128. The HDL-C level of ABCG8 400K allele (TK + KK type) increased after treatment with atorvastatin. After adjusting for age, sex and pretreatment serum TG, The changes of HDL-C in TCG, LDL-C and HDL-C groups were significantly higher than those in carriers of ABCG8 400T homozygote (TT type) (2.8 ± 3.1 1% vs (-0.9 ± 8.4% P = 0.014)). However, the polymorphism of ABCG8 T400K had no significant effect on the changes of TG, TC and LDL-C after 4 weeks of atorvastatin treatment. Conclusion ABCG8 T400K gene polymorphism may affect atorvastatin in the treatment of high-density lipoprotein.